Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients
- 1.6k Downloads
This study explored the self-management strategies utilized by female breast cancer patients to cope with the impact of chemotherapy-induced peripheral neuropathy (CIPN) symptoms. We also examined the variety of taxane-related side effects in women with and without CIPN in order to discriminate the CIPN symptom experience.
A purposive sample of 25 patients treated with docetaxel or paclitaxel were recruited, half with and half without CIPN. Semistructured interviews and patient level data were utilized for this exploratory, descriptive study. Interview data were analyzed with the constant comparative method; patient level data were abstracted from the electronic medical record.
Participants were aged 24–60 years, were currently receiving chemotherapy or within 6 months of having completed treatment, and 14 had CIPN. CIPN impacted routine activities, functions, and behaviors in the areas of domestic, work, and social/leisure life. Multiple self-management and coping strategies to minimize the impact of CIPN symptoms were reported; the focus was on movement to reduce symptoms, attitude awareness, logistics to simplify demands, and environmental change. Women with and without CIPN were similar in the quantity and type of other reported side effects.
CIPN affects breast cancer patients’ routine activities, functions, and behaviors, but they develop management strategies to reduce the impact. The management strategies reported in this study suggest breast cancer patients may adopt interventions that focus on exercise, mindfulness, occupational therapy, and environmental planning toward the goal of reducing the impact of CIPN symptoms on their lives.
KeywordsChemotherapy-induced peripheral neuropathy Symptom management Coping strategies
Conflicts of Interest
- 1.Cancer trends progress report—2009/2010 update (2010). National Cancer Institute, NIH, DHHS, Bethesda, MD. http://progressreport.cancer.gov. Accessed 3 June 2011
- 10.Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRefGoogle Scholar
- 20.In: Bickman L, Rog DJ (eds) Handbook of applied social research methods. Sage Publications, Thousand Oaks, CA, pp 69–100Google Scholar
- 21.Patton M (2002) Qualitative research and evaluation methods. Sage Publications, LondonGoogle Scholar
- 22.Kemper EA, Stringfield S, Teddlie C (2003) Mixed methods sampling strategies in social science research. In: Tashakkori A, Teddlie C (eds) Handbook of mixed methods in social and behavioral research. Sage Publications, Thousand Oaks, CA, pp 273–296Google Scholar
- 26.National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 10 August 2011
- 27.QSR International (2008) Nvivo qualitative data analysis software version 8 edn. QSR InternationalGoogle Scholar
- 29.Velos I (2011) Velos eResearch. Velos, Fremont, CAGoogle Scholar
- 31.National Cancer Institute Symptom Management and Quality of Life Steering Committee: chemotherapy-induced peripheral neuropathy (2009) National Cancer Institute, Rockville, MD. http://transformingtrials.cancer.gov/files/CIPN_CTPM_Final_Executive_Summary_for_CCCT_Aug_2010.pdf. Accessed 3 June 2011
- 32.Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD (2009) Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their Modification PRO task force report. Value Health 12:1075–1083PubMedCrossRefGoogle Scholar